88 Results for "

reversible inhibition

" in MedChemExpress (MCE) Product Catalog:
Products (88)

88 Results for "reversible inhibition" in MCE Product Catalog:

19
19 Publications Verification
Cat. No.: HY-17543
CAS No.: 1572414-83-5
Target:  

Deubiquitinase

Research Areas:  

Cancer

ML-323 is a reversible, potent USP1-UAF1 inhibitor with IC50 of 76 nM in a Ub-Rho assay. The measured inhibition constants of ML-323 for the free enzyme (Ki) is 68 nM.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-15185
CAS No.: 1290543-63-3
Purity:  99.78%
Synonyms: PF-3084014
Target:  

γ-secretase Apoptosis

Research Areas:  

Neurological Disease Cancer

Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-15185B
CAS No.: 1962925-29-6
Purity:  99.63%
Synonyms: PF-3084014 dihydrobromide; PF-03084014 dihydrobromide
Target:  

γ-secretase Apoptosis

Research Areas:  

Cancer

Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-139664
CAS No.: 2170137-61-6
Purity:  99.95%
Target:  

DNA Methyltransferase

Research Areas:  

Cancer

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-13007
CAS No.: 898044-15-0
Purity:  99.79%
Synonyms: PF-03758309
Target:  

PAK Apoptosis

Research Areas:  

Cancer

PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563
CAS No.: 84057-95-4
Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563B
CAS No.: 98717-15-8
Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563A
CAS No.: 132112-35-7
Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-B0563C
CAS No.: 854056-07-8
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-129388B
CAS No.: 2097523-60-7
Purity:  99.64%
Synonyms: CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate
Target:  

Histone Demethylase

Research Areas:  

Inflammation/Immunology Cancer

Pulrodemstat (CC-90011) benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat benzenesulfonate is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-110137
CAS No.: 55368-40-6
Purity:  ≥99.0%
Synonyms: DB75 dihydrochloride; NSC 305831 dihydrochloride
Furamidine dihydrochloride (DB75 dihydrochloride) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine dihydrochloride is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine dihydrochloride is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine dihydrochloride is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine dihydrochloride is also an antiparasite agent .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-129388A
CAS No.: 1821307-10-1
Synonyms: CC-90011; LSD1-IN-7
Target:  

Histone Demethylase

Research Areas:  

Inflammation/Immunology Cancer

Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100414
CAS No.: 261944-46-1
Purity:  99.78%
Synonyms: BYK61359
Target:  

Proton Pump

Research Areas:  

Metabolic Disease

Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (Ki=6.4 nM), with an IC50 of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0313
CAS No.: 514-47-6
Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC50=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139603
CAS No.: 2416417-65-5
Purity:  99.44%
Target:  

YAP

Research Areas:  

Cancer

MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15427
CAS No.: 1133432-49-1
Purity:  98.05%
Target:  

Btk

Research Areas:  

Inflammation/Immunology Cancer

GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA) .
loading...
    loading...
Cat. No.: HY-117769
CAS No.: 13616-29-0
Purity:  ≥99.0%
Research Areas:  

Metabolic Disease

GSK837149A is a selective inhibitor of human Fatty Acid Synthase (FASN) targeting the KR domain. GSK837149A has reversible inhibition effect on FASN and selectivity for type I FASN (Ki=30 nM). GSK837149A is also a competitive inhibitor of NADPH and a non-competitive inhibitor of acetoacetyl-CoA. GSK837149A can be used for the research of obesity and breast cancer .
loading...
    loading...
Cat. No.: HY-B0563S1
CAS No.: 684647-62-9
Ropivacaine-d7 is deuterium labeled Ropivacaine. Ropivacain is a potent?sodium channel?blocker. Ropivacain blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain?management .
loading...
    loading...
Cat. No.: HY-152846
CAS No.: 2268739-68-8
Synonyms: GDC-8264
Flizasertib (GDC-8264) is an orally active, reversible and selective RIP1 inhibitor with Ki app values of 0.00071 μM and 0.0013 μM for human and cynomolgus monkey RIP1 kinase, respectively. Flizasertib blocks RIP1 autophosphorylation but does not affect RIP1 protein stability. Flizasertib inhibits pro-inflammatory cytokines (CCL3, CCL4, and IL-1β) production. Flizasertib results in inhibition of colitis and ileitis. Flizasertib can be used in the research of cardiac surgery-associated acute kidney injury .
loading...
    loading...
Cat. No.: HY-110079
CAS No.: 519178-28-0
Purity:  99.29%
Target:  

IPK Superfamily

Research Areas:  

Cancer

TNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC50s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization[1][2][3].
loading...
    loading...